Volker Heinemann
Impact in
- Oncology top 0.05%
- Colorectal Cancer Treatments and Studies
- Pancreatic and Hepatic Oncology Research
- Cancer Treatment and Pharmacology
- Cancer Research top 0.2%
- Cancer Genomics and Diagnostics
Papers in
- Oncology 483
- Colorectal Cancer Treatments and Studies 253
- Pancreatic and Hepatic Oncology Research 139
- Cancer Treatment and Pharmacology 81
-
- Lung Cancer Treatments and Mutations 74
- Gastric Cancer Management and Outcomes 52
- Co-authors
- Stefan Boeck (123 shared papers)Sebastian Stintzing (204 shared papers)William Plunkett (11 shared papers)Dominik Paul Modest (141 shared papers)Hans‐Joachim Stemmler (39 shared papers)Gerald B. Grindey (4 shared papers)Larry W. Hertel (3 shared papers)Heinz‐Josef Lenz (59 shared papers)
- Journals
- Journal of Clinical Oncology (178 papers)Annals of Oncology (62 papers)European Journal of Cancer (44 papers)Anti-Cancer Drugs (19 papers)British Journal of Cancer (16 papers)
- Partner nations
- GermanyUnited StatesItaly
In The Last Decade
Volker Heinemann
637 papers receiving 20.7k citations
Volker Heinemann's Hit Papers
Peers
Comparison fields: 5 of 157
- Oncology 12.3k
- Cancer Research 3.2k
- Hepatology 1.4k
- Pulmonary and Respiratory Medicine 4.0k
- Pathology and Forensic Medicine 1.9k
Countries citing papers authored by Volker Heinemann
This map shows the geographic impact of Volker Heinemann's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Volker Heinemann with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Volker Heinemann more than expected).
Fields of papers citing papers by Volker Heinemann
This network shows the impact of papers produced by Volker Heinemann. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Volker Heinemann. The network helps show where Volker Heinemann may publish in the future.
Co-authors
The 25 scholars most cited alongside Volker Heinemann, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 683 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Gemcitabine: metabolism, mechanisms of action, and self-potentiation. Hit paper breakdown → | 1995 | 663 |
| 2 | Fluorouracil, Leucovorin, and Irinotecan Plus Cetuximab Treatment and RAS Mutations in Colorectal Cancer Hit paper breakdown → | 2015 | 596 |
| 3 | Prognostic and predictive value of primary tumour side in patients with RAS wild-type metastatic colorectal cancer treated with chemotherapy and EGFR directed antibodies in six randomized trials Hit paper breakdown → | 2017 | 567 |
| 4 | Randomized Phase III Trial of Gemcitabine Plus Cisplatin Compared With Gemcitabine Alone in Advanced Pancreatic Cancer Hit paper breakdown → | 2006 | 552 |
| 5 | nab-Paclitaxel Plus Gemcitabine for Metastatic Pancreatic Cancer: Long-Term Survival From a Phase III Trial Hit paper breakdown → | 2015 | 523 |
| 6 | Prognostic and Predictive Relevance of Primary Tumor Location in Patients With RAS Wild-Type Metastatic Colorectal Cancer Hit paper breakdown → | 2016 | 517 |
| 7 | Prognosis of patients with peritoneal metastatic colorectal cancer given systemic therapy: an analysis of individual patient data from prospective randomised trials from the Analysis and Research in Cancers of the Digestive System (ARCAD) database Hit paper breakdown → | 2016 | 455 |
| 8 | Comparison of the cellular pharmacokinetics and toxicity of 2',2'-difluorodeoxycytidine and 1-beta-D-arabinofuranosylcytosine. | 1988 | 451 |
| 9 | Advances in cancer immunotherapy 2019 – latest trends Hit paper breakdown → | 2019 | 423 |
| 10 | Addressing the challenges of pancreatic cancer: Future directions for improving outcomes Hit paper breakdown → | 2014 | 400 |
| 11 | The relevance of primary tumour location in patients with metastatic colorectal cancer: A meta-analysis of first-line clinical trials Hit paper breakdown → | 2016 | 383 |
| 12 | 1990 | 355 | |
| 13 | 2008 | 348 | |
| 14 | 2006 | 341 | |
| 15 | 2009 | 291 | |
| 16 | Cellular elimination of 2',2'-difluorodeoxycytidine 5'-triphosphate: a mechanism of self-potentiation. | 1992 | 280 |
| 17 | 2016 | 221 | |
| 18 | 2008 | 202 | |
| 19 | 2015 | 189 | |
| 20 | 2016 | 185 |
About Volker Heinemann
Volker Heinemann is a scholar working on Oncology, Pulmonary and Respiratory Medicine, Cancer Research, Molecular Biology and Pathology and Forensic Medicine, having authored 683 papers that have together received 21.1k indexed citations. Recurring topics across this work include Colorectal Cancer Treatments and Studies (253 papers), Pancreatic and Hepatic Oncology Research (139 papers), Cancer Genomics and Diagnostics (99 papers), Cancer Treatment and Pharmacology (81 papers), Lung Cancer Treatments and Mutations (74 papers), Gastric Cancer Management and Outcomes (52 papers), Genetic factors in colorectal cancer (41 papers) and Hepatocellular Carcinoma Treatment and Prognosis (40 papers). The work is most often cited by research in Oncology (12.3k citations), Cancer Research (3.2k citations), Hepatology (1.4k citations), Pulmonary and Respiratory Medicine (4.0k citations) and Pathology and Forensic Medicine (1.9k citations). Volker Heinemann has collaborated with scholars based in Germany, United States and Italy. Frequent co-authors include Stefan Boeck, Sebastian Stintzing, William Plunkett, Dominik Paul Modest, Hans‐Joachim Stemmler, Gerald B. Grindey, Larry W. Hertel, Heinz‐Josef Lenz, Michael Haas and Eric Van Cutsem. Their work appears in journals such as Journal of Clinical Oncology, Annals of Oncology, European Journal of Cancer, Anti-Cancer Drugs and British Journal of Cancer.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.